
FUL
H. B. Fuller Company
Company Overview
| Mkt Cap | $3.14B | Price | $57.34 |
| Volume | 424.27K | Change | +3.48% |
| P/E Ratio | 24.1 | Open | $55.51 |
| Revenue | $3.6B | Prev Close | $55.41 |
| Net Income | $130.3M | 52W Range | $47.56 - $78.68 |
| Div Yield | 0.94% | Target | $70.00 |
| Overall | 65 | Value | 85 |
| Quality | -- | Technical | 45 |
No chart data available
About H. B. Fuller Company
H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Construction Adhesives. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and health and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for tile setting, commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.
Latest News
Fulcrum Lithium Expands Alkali Flats Targets with New Survey
Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential
Fulcrum Therapeutics Reports Q3 2025 Progress and Financials
Analysts Are Bullish on Top Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Fulcrum Therapeutics (FULC)
Oppenheimer Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FUL | $57.34 | +3.5% | 424.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |